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Female sexual dysfuntion is relatively common, 
but women seldom seek medical help. This article 
discusses the issues around female sexual dysfunction 
by reviewing the available literature, including 
publications written or cited by the International 
Consultation on Sexual Medicine, the Journal of Sexual Medicine 
(official journal of the International Society of Sexual Medicine) and 
a personal archive of references. 
Talking about sexual issues
An online survey of 3  807 healthy volunteers indicated that 40% of 
women did not discuss sexual problems with their clinician.[1] Research 
suggests that healthcare providers may feel uncomfortable discussing 
sexual health issues with their patients. The reasons may include: (i) a 
lack of training and skills to deal with patient concern; (ii) embarrassment 
when talking about sex; (iii) concern about offending or embarrassing the 
patient; (iv) underestimating the prevalence of sexual dysfunctions; and 
(v) underestimating the impact sexual complaints have on a patient’s 
health.[2] A multinational study revealed that while half of sexually 
active participants had a sexual problem, only 19% and 9% had sought 
medical care and had been asked about sexual health in the last 3 years, 
respectively.[3] Female sexual problems are highly prevalent, affecting 
up to 43% of women.[4,5] Between a third and half of these women 
describe their problem/s as distressing,causing a major impact on their 
quality of life and interpersonal relationships.[4,6] The lack of effective 
and safe treatment options may also have an impact.[2] However, sexual 
health questions should be part of a normal review of systems starting 
with a normalising statement (e.g. ‘It is part of my routine to ask about 
sexual health’) and continuing with an open-ended question (e.g. ‘Do 
you have any concerns?’).[7] Basic screening for sexual function should 
include two key questions: ‘Are you currently involved in a sexual 
relationship?’ and ‘Are your sexual partners men, women, or both?’[7] 
The permission, limited information, specific suggestions and intensive 
therapy (PLISSIT) model is one of intervention for sexual problems.[8]
Permission
Open-ended questions give the patient permission to talk about her 
sexual concerns, give reassurance that her feelings are normal, and 
validate and legitimise the patient’s complaint (e.g. ‘Tell me about any 
sexual concern/problem you would like to discuss’ and ‘How does the 
problem affect your life and relationship?’).[7]
Limited information 
Address topics in the time available and suggest a follow-up 
appointment to focus on sexual health concerns. Provide information 
about anatomy, physiology, normal sexual response, sexual changes 
occurring with age, medication use (e.g. antidepressants), or the 
influence of comorbid medical conditions (e.g. depression). Dispel 
myths about sexual concerns. 
Specific suggestions
Offer specific suggestions and solutions to try to treat the complaint 
(e.g. management of comorbid conditions or reassessment of 
medications that may affect sexual function).[7,9] Further suggestions 
may include: improved time/stress management skills; improved 
exercise and diet habits; if privacy is a problem – locking the bedroom 
door; addressing sexual boredom – spending time as a couple (e.g. 
date nights), changing the sexual routine, exploring sexuality via 
masturbation, using accessories; and education about sexual response 
(e.g. women in long-term relationships may not feel spontaneous 
desire). 
Intensive therapy
It may be necessary to refer the patient for more specific 
investigations and intensive therapy to qualified specialists, including 
sex therapists, couples counsellors, cognitive-behavioural therapists, 
physiotherapists, and medical or surgical subspecialists. Any patient 
with a sexual issue that exceeds your comfort level or expertise should 
be referred.
Female sexual response
Masters and Johnson described the human sexual response as a 
linear process of distinct phases of excitement, arousal, orgasm and 
resolution.[10] This model was later modified into a three-phase model 
of desire, arousal and orgasm.[11] More recently, a circular sexual 
response cycle of overlapping phases has been described.[12] This 
more complex, non-linear model includes emotional and relational 
factors as well as external and cognitive sexual stimuli. Desire may/
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may not be present initially, but may be triggered by arousal to 
appropriate sexual stimuli. 
Pathophysiology
An integrative approach is required, with attention to the biological 
(physical health, neurobiology and endocrine function), psychological 
(anxiety and depression), relational (current and past) and contextual 
(life stressors) contributors to the sexual problem,[13] as well as the 
predisposing, precipitating and maintaining factors relating to the 
disorder.[14] Involving the partner is advantageous. 
Prevalence of conditions
A wide range of prevalence estimates of female sexual dysfunctions 
(FSDs) have been reported. When associated distress was considered, 
a survey found the prevalence of hypoactive sexual desire disorder 
to be 16%, sexual arousal disorder 7%, orgasmic disorder 8%, and 
dyspareunia 1%.[15] An overlap of disorders is common. 
Clinical assessment 
Detailed history
By asking the patient open-ended questions, she should be 
encouraged to describe her complaint in her own words. Attention 
should be paid to whether it has always been present (lifelong) or 
has been acquired, whether it is situational, generalised or related to 
specific situations (e.g. the partner’s sexual difficulty/behaviour), and 
whether she experiences difficulties with desire, arousal, orgasm or 
pain or a combination of complaints.[16] The degree of distress should 
be assessed. 
Biomedical factors include diseases, drugs and hormones, and 
should be assessed in detail to include a gynaecological and an 
obstetric history, contraception methods, a medical and surgical 
history, and medication use (including over-the-counter medications, 
alcohol and illicit drugs).[16] 
The medical history may include conditions that interfere with 
sexual function, e.g. lifestyle (nutrition, sleep), cardiovascular 
disease, diabetes, endocrinopathies (thyroid), urinary (incontinence), 
renal, or neurological (multiple sclerosis, Parkinson’s disease) 
problems, trauma and cancer.[16] Psychological factors, including 
individual psychological (anxiety and depression), relational and 
social factors, should be discussed. History taking should include 
negative early experiences, sexual abuse and relationship factors.[16] 
Medication may have an impact on FSDs, e.g. antidepressants and 
mood stabilisers (selective serotonin re-uptake inhibitors (SSRIs)), 
anticonvulsants, hormones and hormone antagonists (hormonal 
contraception, anti-androgens, gonadotropin-releasing hormone 
(GnRH) agonists), antihypertensives (beta-blockers, alpha-blockers, 
diuretics), cardiovascular agents, and histamine receptor blockers.[17]
Psychometric measures
The Brief Sexual Symptom Checklist for Women, a self-reporting 
tool, asks four questions regarding a patient’s satisfaction, sexual 
problem and whether she wishes to address these issues.[16] More 
detailed screening tools may be used, although these should not be 
a substitute for a thorough sexual, medical and psychosocial history. 
Examination
A general medical examination is indicated when relevant and 
should be guided by the medical history. A genital examination is 
recommended for good medical care, reassurance and education. 
A normal examination may be highly informative. The patient’s 
beliefs, perceptions and attitudes about her body can be assessed. 
An examination is mandatory if there is lack of sexual interest due 
to endocrine changes, a combination of dysfunctions or sexual 
pain. The examination includes careful inspection for changes or 
abnormalities (e.g. signs of inflammation, scarring, skin quality or 
colour, atrophy, fissures, erosions, ulcers, and vaginal pH), culture 
of discharge if present, careful palpation, if appropriate, with pain 
mapping and assessment of the pelvic floor, muscular tone and 
strength.[18] An ultrasound scan or a laparoscopic examination may 
be required if an abnormality is suspected.
Laboratory testing
Testing for glucose, haemoglobin level, thyroid, prolactin and 
reproductive hormones (luteinising hormone, and follicle-stimulating 
hormone) to rule out metabolic or pituitary dysfunction may be 
required.[18] Oestrogen or androgen deficiencies are usually detected 
by history and examination.
Definitions, diagnostic criteria and 
treatment options
The Diagnostic and Statistical Manual of Mental Disorders version 5 
(DSM-5)[19] states that a sexual dysfunction must have persisted for a 
minimum of 6 months, must cause clinically significant distress, is not 
better explained by a non-sexual mental disorder or as a consequence 
of severe relationship stress or other significant stressors, and is not 
attributed to the effects of a substance or medication or another 
medical condition. Clinicians should specify whether the condition 
is lifelong or acquired and generalised or situational.
Female sexual interest/arousal disorder
Female sexual interest/arousal disorder is defined as the lack of or 
significantly reduced sexual interest/arousal with at least three of the 
following: absent/reduced interest in sexual activity; absent/reduced 
sexual/erotic thoughts or fantasies; no/reduced initiation of sexual 
activity, and typically unreceptive to a partner’s attempts to initiate; 
absent/reduced sexual excitement/pleasure during sexual activity 
in almost all or all (75 - 100%)  sexual encounters (in identified 
situational contexts or, if generalised, in all contexts); absent/reduced 
sexual interest/arousal in response to any internal or external sexual/
erotic cues (e.g. written, verbal, visual); absent/reduced genital 
or non-genital sensations during sexual activity in  almost all or all 
(75 - 100%)  sexual encounters (in identified situational contexts or, if 
generalised, in all contexts).[19]
Treatment should focus on providing specific information regarding 
desire and variations with age, relationship duration, lifestyle changes 
or the female sexual response cycle, including motivations for 
sexual intimacy.[20] Techniques that encourage focusing on awareness 
of genital response, including cognitive therapy, behavioural and 
mindfulness exercises, have been shown to improve arousal.[21] 
Pharmacotherapy use is limited. Decreased androgen levels do 
not correlate well with decreased desire.[22] However, although 
not approved for use in South Africa, testosterone (300  µg daily), 
administered transdermally, has been shown to benefit sexual desire 
in oestrogen-repleted, naturally and surgically postmenopausal 
women. [23] Topical and systemic oestrogen improves vaginal 
lubrication for vaginal atrophy.[24] In postmenopausal women, 
tibolone has been associated with significant increases in sexual 
desire and arousal compared with placebo.[25] The Eros clitoral 
therapy device, designed to improve arousal, increases clitoral blood 
flow.[26] Use of water-based lubricants and moisturisers is advised. 
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Female orgasmic disorder 
Female orgasmic disorder (FOD) is defined as the presence of either 
of the following symptoms and experienced on almost all or all 
(75 - 100%) occasions of sexual activity: marked delay in, marked 
infrequency of, or absence of orgasm; markedly reduced intensity of 
orgasmic sensations.[19]
Treatment recommendations include a combination of cognitive 
and behavioural techniques, directed masturbation training, 
and anxiety reduction techniques, with mindfulness[27] and 
yoga practice[28] as possible adjuncts. Education regarding coital 
positioning with maximum glans clitoral stimulation during vaginal 
intercourse has been shown to be beneficial. Hormone treatments 
for postmenopausal women may be indicated, with more research 
recommended in women with FOD as a primary complaint. One 
study has shown phosphodiesterase type 5 (PDE5) inhibitors to 
be beneficial for the adverse side-effects of SSRIs on orgasmic 
functioning.[29] 
Genitopelvic pain/penetration disorder 
This disorder is defined as persistent or recurrent difficulties 
with one (or more) of the following: vaginal penetration during 
intercourse; marked vulvovaginal or pelvic pain during vaginal 
intercourse or penetration attempts; marked fear of or anxiety 
regarding vulvovaginal or pelvic pain in anticipation of, during, or as 
a result of vaginal penetration; marked tensing or tightening of the 
pelvic floor muscles during attempted vaginal penetration.[19]
Sexual pain disorders may have a biological (e.g. vulvovaginal 
infections, dermatoses, hormonal, vascular, neurological, or 
iatrogenic), psychosexual and functional (pelvic floor hypertonicity) 
component.[30] Context-related factors may contribute to this.[31] A 
multisystemic, multidisciplinary approach is advised when treating 
female sexual pain, with attention to mucous membrane, pelvic 
floor experience of pain, sexual and relationship functioning, and 
psychosocial adjustment/sexual abuse.[32] 
Organic disorders (e.g. inflammatory, dermatological, infectious, 
neoplastic) should be treated appropriately (e.g. topical oestrogens, 
steroids, antibiotics, surgical). Pain management includes 
pharmacotherapy (systemic and/or topical) with tricyclic anti-
depressants and topical lidocaine. Further research regarding 
treatment outcomes is needed. Vestibulectomy is recommended as a 
last resort when distinct mucosal involvement occurs.[33] 
Where tense pelvic muscles contribute, pelvic floor physio-
therapy,[30] cognitive behavioural therapy,[34] and Kegel’s and 
relaxation exercises may be beneficial. Preventive hygiene measures 
are encouraged (e.g. avoiding soaps/douches, nylon underwear and, if 
an irritant, vulvar contact with semen). Sitz baths may help to reduce 
inflammation and symptoms.[33] While pain is present, avoidance of 
penetration during sexual activity may be advised to break the cycle 
of avoidance and catastrophism. Counselling regarding restarting of 
the sexual relationship is recommended.[33] 
If phobic avoidance of penetration is present, treatments targeting 
fear-avoidance issues, progressive desensitisation by vaginal dilatation 
using fingers or vaginal trainers, education on sexuality, and Kegel’s 
and relaxation exercises may help to decrease penetration fear and 
anxiety.[35] If considered necessary, treatment for sexual trauma 
should occur prior to treatment for sexual dysfunction.[35]
Conclusion
Female sexual problems are highly prevalent. Patients want to discuss 
concerns about their sexual health with their healthcare provider. An 
integrative approach is required, with attention paid to the biological, 
psychological, relational and contextual contributors to the sexual 
problem. FSDs include interest/arousal, orgasmic and genitopelvic 
pain/penetration disorders.
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